DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus ...

Bioventus Inc. (BVS) announced the completion of its earlier-announced divestiture of the Advanced Rehabilitation business of its subsidiary, Bioness, yesterday. In October 2024, BVS inked a definitive agreement to sell its business to private equity firm, Accelmed Partners (“Accelmed”).Per Bioventus’ management, the divestiture of the Advanced Rehabilitation business is expected to reduce the company’s annual revenues by approximately $50 million and annual adjusted EBITDA by approximately $6 million.The l ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1020 individual stocks in the Medical sector. Collectively, these com ...

Bioventus Inc. (NASDAQ:BVS) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instruct ...

November 5, 2024 Innovations For Active Healing Third Quarter 2024 Financial Results Agenda and Speakers Rob Claypoole President and Chief Executive Officer Update on 2024 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q3 2024 Results Update to 2024 Financial Guidance Forward Looking Statements and Use of Estimates Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sect ...

Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.19, delivering a surprise of 171.43%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Bioventus, which belongs to the Zac ...

Exhibit 99.1 Bioventus Reports Third Quarter Financial Results • Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* Growth • Q3 Gross Margin Expanded 200 bps • Q3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, NC – November 5, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, ...

Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. “We delivered strong financial results in the thi ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bioventus (BVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Bioventus is one of 1024 companies in the Medical group. The Medical group currently sits ...

Bioventus (BVS) is expected to report third-quarter 2024 earnings next month. The Zacks Consensus Estimate for sales and earnings is pegged at $132.6 million and 6 cents per share, respectively.Estimates for Bioventus’ 2024 and 2025 earnings per share (EPS) have remained consistent in the past 60 days at 40 and 45 cents, respectively. The company delivered an earnings surprise of 171.43% in the last reported quarter. Image Source: Zacks Investment ResearchBVS’ Earnings Surprise HistoryThe company’s earnings ...